Drug block of the hERG potassium channel: Insight from modeling

Proteins: Structure, Function and Genetics

Volumn 68, Issue 2, 2007, Pages 568-580

  Stansfeld, Phillip J ^a   Gedeck, Peter ^b   Gosling, Martin ^b   Cox, Brian ^b   Mitcheson, John S ^a   Sutcliffe, Michael J ^c,d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Drug block; Gating; Helix motion; hERG; Molecular modeling; Potassium channel

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; ASTEMIZOLE; CETIRIZINE; CHLOROQUINE; CISAPRIDE; CLOFILIUM; DOFETILIDE; DRONEDARONE; FEXOFENADINE; FLUVOXAMINE; GLYCINE; IBUTILIDE; LIGAND; LORATADINE; MOSAPRIDE CITRATE; PIPERANOMETOZINE; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; SERTINDOLE; TERFENADINE;

AMINO ACID SEQUENCE; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG BINDING SITE; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CRYSTALLOGRAPHY, X-RAY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEURONS; POTASSIUM CHANNEL BLOCKERS; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

PROKARYOTA;

EID: 34250836484     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21400     Document Type: Article

References (75)

1. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299-307.
2. Tseng GN. I(Kr): the hERG channel. J Mol Cell Cardiol 2001; 33:835-849.
3. Vandenberg JI, Walker BD, Campbell TJ. HERG K+ channels: friend and foe. Trends Pharmacol Sci 2001;22:240-246.
4. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
5. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003;2:439-447.
6. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005;25:133-166.
7. Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005;26:119-124.
8. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-3442.
9. Liu J, Zhang M, Jiang M, Tseng GN. Structural and functional role of the extracellular s5-p linker in the HERG potassium channel. J Gen Physiol 2002;120:723-737.
10. Torres AM, Bansal PS, Sunde M, Clarke CE, Bursill JA, Smith DJ, Bauskin A, Breit SN, Campbell TJ, Alewood PF, Kuchel PW, Vandenberg JI. Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic α-helix in C-type inactivation. J Biol Chem 2003;278:42136-42148.
11. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, Mackinnon R. Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell 1998;95:649-655.
12. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000;115:229-240.
13. Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ Res 1996;78:499-503.
14. Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC. Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 2001;60:244-253.
15. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular determinants of HERG channel block. Mol Pharmacol 2006; 69:1709-1716.
16. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-12333.
17. Perry M, De Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 2004;66:240-249.
18. Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 2006;69:509-519.
19. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004;279:10120- 10127.
20. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002;277:23587-23595.
21. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003;63:1051-1058.
22. Cavalli A, Poluzzi E, De Ponti F, Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem 2002;45:3844-3853.
23. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 1998;280:69-77.
24. Ishii K, Kondo K, Takahashi M, Kimura M, Endoh M. An amino acid residue whose change by mutation affects drug binding to the HERG channel. FEBS Lett 2001;506:191-195.
25. Gessner G, Zacharias M, Bechstedt S, Schonherr R, Heinemann SH. Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol Pharmacol 2004;65:1120-1129.
26. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, Mitcheson JS. The low-potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping. Mol Pharmacol 2004;66:1201-1212.
27. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002;417:515-522.
28. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-1835.
29. Jiang Y, Lee A, Chen J, Ruta V, Cadene M, Chait BT, MacKinnon R. X-ray structure of a voltage-dependent K+ channel. Nature 2003;423:33-41.
30. Osterberg F, Aqvist J. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods. FEBS Lett 2005;579:2939-2944.
31. Farid R, Day T, Friesner RA, Pearlstein RA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg Med Chem 2006; 14:3160-3173.
32. Rajamani R, Tounge BA, Li J, Reynolds CH. A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorg Med Chem Lett 2005;15:1737-1741.
33. Zhou Y, Morais-Cabral JH, Kaufman A, MacKinnon R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature 2001;414:43-48.
34. Magidovich E, Yifrach O. Conserved gating hinge in ligand- and voltage-dependent K+ channels. Biochemistry 2004;43:13242-13247.
35. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. The open pore conformation of potassium channels. Nature 2002;417:523-526.
36. Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 2002;99:12461-12466.
37. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999;292:195-202.
38. Jones DT. Do transmembrane protein superfolds exist? FEBS Lett 1998;423:281-285.
39. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics 2000;16:404-405.
40. O'Donovan C, Martin MJ, Gattiker A, Gasteiger E, Bairoch A, Apweiler R. High-quality protein knowledge resource: SWISS-PROT and TrEMBL. Brief Bioinform 2002;3:275-284.
41. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242.
42. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389-3402.
43. Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, Doyle DA. Crystal structure of the potassium channel KirBac1.1 in the closed state. Science 2003;300:1922-1926.
44. Zhou M, Morais-Cabral JH, Mann S, MacKinnon R. Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature 2001;411:657-661.
45. Long SB, Campbell EB, Mackinnon R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005;309:897-903.
46. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
47. Gouet P, Courcelle E, Stuart DI, Metoz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 1999; 15:305-308.
48. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779-815.
49. Fiser A, Do RK, Sali A. Modeling of loops in protein structures. Protein Sci 2000;9:1753-1773.
50. Suhre K, Sanejouand YH. ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res 2004;32(Web Server issue):W610-W614.
51. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004;50:93-101.
52. Schiffer M, Chang CH, Stevens FJ. The functions of tryptophan residues in membrane-proteins. Protein Eng 1992;5:213-214.
53. Shealy RT, Murphy AD, Ramarathnam R, Jakobsson E, Subramaniam S. Sequence-function analysis of the K+-selective family of ion channels using a comprehensive alignment and the KcsA channel structure. Biophys J 2003;84:2929-2942.
54. Rajamani S, Anderson CL, Anson BD, January CT. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation 2002;105:2830-2835.
55. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM. Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 1998;82(3):386-395.
56. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998; 286(2):788-793.
57. Morais-Cabral JH, Zhou Y, MacKinnon R. Energetic optimization of ion conduction rate by the K+ selectivity filter. Nature 2001;414:37-42.
58. Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, Annunziato L. Molecular basis for the lack of HERG K+ channel block-related eardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998;54:113-121.
59. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003;139:887-898.
60. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000;57:367-374.
61. Ridley JM, Milnes JT, Witchel HJ, Hancox JC. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun 2004;325:883-891.
62. Scherer CR, Lerche C, Decher N, Dennis AT, Maier P, Ficker E, Busch AE, Wollnik B, Steinmeyer K. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. Br J Pharmacol 2002; 137:892-900.
63. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267:727-748.
64. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP. Empirical scoring functions. I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997;11:425-445.
65. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-623.
66. DeLano WL.The PyMOL Molecular Graphics System. 2002; http://www.pymol. org.
67. Larsson HP, Elinder F. A conserved glutamate is important for slow inactivation in K+ channels. Neuron 2000;27:573-583.
68. Ortega-Saenz P, Pardal R, Castellano A, Lopez-Barneo J. Collapse of conductance is prevented by a glutamate residue conserved in voltage-dependent K(+) channels. J Gen Physiol 2000; 116:181-190.
69. Loots E, Isacoff EY. Molecular coupling of S4 to a K+ channel's slow inactivation gate. J Gen Physiol 2000;116:623-635.
70. Fernandez D, Ghanta A, Kinard KI, Sanguinetti MC. Molecular mapping of a site for Cd2+-induced modification of human ether-a-go-go-related gene (hERG) channel activation. J Physiol (London) 2005;567:737-755.
71. Yau WM, Wimley WC, Gawrisch K, White SH. The preference of tryptophan for membrane interfaces. Biochemistry 1998;37: 14713-14718.
72. Mitcheson JS. Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine. Br J Pharmacol 2003;139:883-884.
73. Crumb WJ, Jr. Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 2000;292:261-264.
74. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001;299: 1007-1012.
75. Ament PW, Paterson A. Drug interactions with the nonsedating antihistamines. Am Fam Physician 1997;56:223-231.